Targeted in vivo Position Abintus as a pioneer of in vivo genetic medicines with a modular delivery platform, offering potential for off-the-shelf, patient-native immune cell engineering that could appeal to partners seeking streamlined, inside-the-body therapies.

Strategic collaborations Highlight past funding and support from Takeda Ventures and LLS TAP to attract biotech investors and strategic partners seeking validated early-stage programs and experienced leadership in immuno-oncology and gene delivery.

Clinical lineage Leverage 20+ years of探索 and 350 patients through Phase 3 experience to build credibility with co-development prospects, pharmaceutical licensors, and contract development/manufacturing organizations (CDMOs) focusing on in vivo modalities.

Leadership hiring Capitalize on recent senior hires in synthetic biology to engage potential collaborators and customers; target academia-to-industry partnerships and joint development opportunities in CAR-NK, CAR-T, TCR-T, and related platforms.

Global expansion readiness Emphasize readiness to scale through multi-therapy applications across oncology, autoimmune, infectious, and genetic diseases, inviting pharma partners to co-create programs across diverse gene delivery systems and cell types.